Search for Articles on Google by:
Po-Yao HsuMing-Lun Yeh
Chung-Feng Huang
Chia-Yen Dai
Ming-Lung Yu
Jee-Fu Huang
Wan-Long Chuang
Hepatitis B reactivation with hepatic decompensation after the use of direct-acting antiviral agents in a patient with chronic Hepatitis B and C coinfection
Po-Yao Hsu |
Ming-Lun Yeh |
Chung-Feng Huang |
Chia-Yen Dai |
Ming-Lung Yu |
Jee-Fu Huang |
Wan-Long Chuang |
Article Number: irjmbs.19.007 | Pages: 38-41 | Vol.4 (4), October, 2019 | DOI: https://doi.org/10.15739/irjmbs.19.007
Received: August 12, 2019 Accepted: October 5, 2019 Published: October 24, 2019
Abstract
In recent years, direct-acting antiviral agents (DAAs) have become the major therapy for Hepatitis C virus (HCV) infection and chronic Hepatitis C (CHC). However, Hepatitis B virus (HBV) reactivation (HBVr) remains an important issue among patients with HBV/HCV coinfection when receiving DAAs for CHC. The severity of HBVr-induced Hepatitis may range from a mild to a severe form of liver injury. In this study, we present a rare case of HBVr leading to a decompensated state and jaundice in a 72-year-old man during DAA treatment. His decompensated state subsequent to HBVr, fortunately improved after initiating oral antiviral treatment for HBV. Our case highlights the importance of the pretreatment evaluation of patients for HBV, monitoring potential HBVr, and the initiation of HBV antiviral therapy in HBV/HCV coinfected patients.
Keywords: Direct-acting antiviral agents, chronic Hepatitis C, Hepatitis B virus reactivation, decompensation
How to Cite this Article
Author(s) retain the copyright of this article. Author(s) agree that this article remain permanently open access under the terms of the Creative Commons Attribution License 4.0 International License.